Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

The updated recommendation lowers the recommended age for RSV vaccination from 60 to 50 years in adults who are at high risk. The US Centers for Disease Control and Prevention’s (CDC ...

Designed to help parents understand which RSV vaccines or immunizations they are eligible for as part of Australia's new RSV Maternal and Infant Immunization Program, the guidance tool provides ...

The ACIP has now recommended the use of GSK’s RSV vaccine, Arexvy, and PFE’s RSV vaccine, Abrysvo, in adults aged 50-59 who are at high risk of severe RSV disease. Individuals with underlying ...

This is "a call to action," she said. There are currently three vaccines approved for RSV; two of them -- GSK's Arexvy and Pfizer's Abrysvo -- are protein subunit vaccines, while Moderna's mResvia ...

This includes ABRYSVO ® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to ...

In a recent final analysis of a phase 3 trial, the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine maintained high efficacy and a favorable safety profile against RSV-associated ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy ...

especially the vulnerable to take the Respiratory Syncytial Virus (RSV) vaccine as a proactive measure to protect against the virus. According to the Ministry, the RSV vaccine helps by preventing ...

This includes ABRYSVO® (Respiratory Syncytial Virus Vaccine), which in October 2024 ... can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and ...